Analystreport

CASI Pharmaceuticals Inc (NASDAQ: CASI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.50 price target on the stock.

CASI Pharmaceuticals, Inc. - Ordinary Shares  (CASI) 
Last casi pharmaceuticals, inc. - ordinary shares earnings: 11/12 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: casipharmaceuticals.com/investor-relations